From 'real' pharmacotherapeutic problems in schizophrenia to an 'ideal' pharmacodynamic profile for neuroleptics

A. C. Altamura

Research output: Contribution to journalArticlepeer-review

Abstract

The 'ideal' pharmacodynamic profile of a neuroleptic stems from the neurochemical data indicating an involvement of not just D2 receptors but also other DA, 5-HT and glutamate receptors in the pathogenesis of schizophrenia. Moreover, this 'ideal' drug should lack anticholinergic and α-adrenolytic activity. A broader spectrum of clinical activity and a better tolerability could be expected.

Original languageEnglish
Pages (from-to)219-220
Number of pages2
JournalEuropean Neuropsychopharmacology
Volume4
Issue number3
DOIs
Publication statusPublished - 1994

Keywords

  • DA receptors subtypes
  • Drug resistance
  • Drug treatment
  • Schizophrenia
  • Serotonin

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Fingerprint

Dive into the research topics of 'From 'real' pharmacotherapeutic problems in schizophrenia to an 'ideal' pharmacodynamic profile for neuroleptics'. Together they form a unique fingerprint.

Cite this